## AMENDMENTS TO THE CLAIMS

1. (Previously presented) A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels in a mammal comprising the following compounds:

Genus A,



wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, $CF_3$, $OCF_3$. $CONH_2$, CONHR and $NHCOR_1$;

wherein R is selected from the group consisting of H, $CH_3$, $C_2H_5$, $C_3H_7$, $C_4H_9$, $CH_2Ph$, $CH_2C_6H_4$-F(p-), $COCH_3$, $CO_2CH_2CH_3$, aminoalkyl and dialkylaminoalkyl; and

wherein $R_1$ is a heterocyclic ring containing one heteroatom or substituted heterocyclic ring containing one heteroatom; and

wherein $R_2$ is selected from the group consisting of aryl, heteroaryl, thiophene, pyridyl, thiazolyl, isoxazolyl, oxazolyl, pyrimidinyl, substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, cycloaryl, cycloheteroaryl, quinolinyl, isoquinolinyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoqunolinyl, multi-ring cycloaryl, multi-ring cycloheteroaryl, benzyl, heteroaryl-methyl, substituted benzyl, substituted heteroaryl-methyl alkyl, dialkylaminoalkyl, cycloalkyl, cycloalkyl containing 1-3 heteroatoms, substituted cycloalkyl, substitute cycloalkyl containing 1-3 heteroatoms, multi-ring cycloalkyl, multiring cycloalkyl containing 1-3 heteroatoms, fused-ring aliphatic, fused-ring aliphatic containing 1-3 heteroatoms, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl,

pyrrole, piperidine, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl, heterocyclic ring, and substituted heterocyclic ring;

wherein at least one of $R_1$ and $R_2$ are aromatic groups or heteroaromatic groups; and

wherein $R_1$ and $R_2$ cannot both be phenyl groups.

2. (Previously presented) The pharmaceutical composition of Claim 1, wherein the substituent is selected from the group consisting of alkyl, aryl, $CF_3$, $CH_3$, $OCH_3$, OH, CN, $CONH_2$, CONHR, $CONR_1R_2$, COOR and COOH.

3. (Original) The pharmaceutical composition of Claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

4. (Original) The pharmaceutical composition of Claim 3, wherein said at least one additional ingredient is selected from the group consisting of a short-acting $\beta_2$-adrenergic agonist, a long-acting $\beta_2$-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

5. (Currently amended) The pharmaceutical composition of Claim 1, wherein the compound is selected from the group consisting of:



(888),



(1239),



(1240),



(1256),



(1258),



(1259),



(1301),



(1302),



(1303)

6. (Previously presented) A method for treating or preventing an allergic reaction in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of following formula:

Genus A,



wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, $CF_3$, $OCF_3$. $CONH_2$, CONHR and $NHCOR_1$;

wherein R is selected from the group consisting of H, $CH_3$, $C_2H_5$, $C_3H_7$, $C_4H_9$, $CH_2Ph$, $CH_2C_6H_4$-F(p-), $COCH_3$, $CO_2CH_2CH_3$, aminoalkyl and dialkylaminoalkyl; and

wherein $R_1$ is a heterocyclic ring containing one heteroatom or substituted heterocyclic ring containing one heteroatom; and

wherein $R_2$ is selected from the group consisting of aryl, heteroaryl, thiophene, pyridyl, thiazolyl, isoxazolyl, oxazolyl, pyrimidinyl, substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, cycloaryl, cycloheteroaryl, quinolinyl, isoquinolinyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoqunolinyl, multi-ring cycloaryl, multi-ring cycloheteroaryl, benzyl, heteroaryl-methyl, substituted benzyl, substituted heteroaryl-methyl alkyl, dialkylaminoalkyl, cycloalkyl, cycloalkyl containing 1-3 heteroatoms, substituted cycloalkyl, substitute cycloalkyl containing 1-3 heteroatoms, multi-ring cycloalkyl, multiring cycloalkyl containing 1-3 heteroatoms, fused-ring aliphatic, fused-ring aliphatic containing 1-3 heteroatoms, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, pyrrole, piperidine, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted

piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl, heterocyclic ring, and substituted heterocyclic ring;

wherein at least one of $R_1$ and $R_2$ are aromatic groups or heteroaromatic groups.

7. (Original) The method of Claim 6, further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

8. (Original) The method of Claim 7, wherein said additional ingredient is selected from the group consisting of a short-acting $\beta_2$-adrenergic agonist, a long-acting $\beta_2$-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

9. (Currently amended) The method of Claim 6, wherein the compound is selected from the group consisting of:



(888),



(1239),



(1240),



(1256),



(1258)



(1259)



(1301)



(1302)



(1303)

10. (Previously presented) A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of following formula:

Genus A,



wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, $CF_3$, $OCF_3$. $CONH_2$, CONHR and $NHCOR_1$;

wherein R is selected from the group consisting of H, $CH_3$, $C_2H_5$, $C_3H_7$, $C_4H_9$, $CH_2Ph$, $CH_2C_6H_4$-F(p-), $COCH_3$, $CO_2CH_2CH_3$, aminoalkyl and dialkylaminoalkyl; and

wherein $R_1$ is a heterocyclic ring containing one heteroatom or substituted heterocyclic ring containing one heteroatom; and

wherein $R_2$ is selected from the group consisting of aryl, heteroaryl, thiophene, pyridyl, thiazolyl, isoxazolyl, oxazolyl, pyrimidinyl, substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, cycloaryl, cycloheteroaryl, quinolinyl, isoquinolinyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoqunolinyl, multi-ring cycloaryl, multi-ring cycloheteroaryl, benzyl, heteroaryl-methyl, substituted benzyl, substituted heteroaryl-methyl alkyl, dialkylaminoalkyl, cycloalkyl, cycloalkyl containing 1-3 heteroatoms, substituted cycloalkyl, substitute cycloalkyl containing 1-3 heteroatoms, multi-ring cycloalkyl, multiring cycloalkyl containing 1-3 heteroatoms, fused-ring aliphatic, fused-ring aliphatic containing 1-3 heteroatoms, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, pyrrole, piperidine, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl, heterocyclic ring, and substituted heterocyclic ring;

wherein at least one of $R_1$ and $R_2$ are aromatic groups or heteroaromatic groups.

11. (Original) The method of Claim 10 further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

12. (Original) The method of Claim 11, wherein said additional ingredient is selected from the group consisting of a short-acting $\beta_2$-adrenergic agonist, a long-acting $\beta_2$-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

13. (Currently amended) The method of Claim 10, wherein the compound is selected from the group consisting of:



(888),



(1239),



(1240),



(1256),


(1258)


(1259)


(1301)


(1302)


(1303)

14. (Previously presented) The pharmaceutical composition of Claim 1, wherein $R_2$ is aliphatic.

15. (Previously presented) The pharmaceutical composition of Claim 1, wherein the compound is selected from the group consisting of



(1239),



(1240),



(1256),



(1258)

16. (Previously presented) The pharmaceutical composition of Claim 1, wherein the compound is



(1256)